CBV refers to Cytoxan , BCNU , and VP-16 , three drugs in a chemotherapy regimen commonly given to lymphoma patients in conjunction with stem cell therapySkeel, Roland T. Handbook of Cancer Chemotherapy, 6th Edition. Philadelphia: Lipincott, Williams, & Wilkins, 2003. Page 172-3, Table 5.4: "Common preparative regimens for high-dose therapy without total-body irradiation." CBV is usually given in high doses to patients who have relapsed or who have refractory disease and cannot benefit from standard chemotherapy. Since a patient's bone marrow is virtually guaranteed not to survive a course of CBV, the receiving patient must receive a transplant (allogenic or autologous, depending on his or her condition) of stem cells (formerly referred to as a bone marrow transplant) to replace the patient's own hemopoietic ("blood-forming") stem cells.